tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Christopher Liu, 17 are a BUY (73.91%), 6 are a HOLD (26.09%).
Analyst Christopher Liu, currently employed at LUCID CAPITAL, carries an average stock price target met ratio of 34% that have a potential upside of 21.34% achieved within 120 days. Previously, Christopher Liu worked at LEERINK.
Christopher Liu’s has documented 46 price targets and ratings displayed on 10 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on CRDF, Cardiff Oncology at 30-Jun-2026.
Analyst best performing recommendations are on LYEL (LYELL IMMUNOPHARMA).
The best stock recommendation documented was for COGT (COGENT BIOSCIENCES) at 6/10/2022. The price target of $15 was fulfilled within 68 days with a profit of $7.13 (90.6%) receiving and performance score of 13.32.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date of last PT
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Buy Since 21-Jan-2026
$55
$23.98 (77.30%)
$55
21 days ago
(16-Sep-2026)
5/11 (45.45%)
$22.46 (69.02%)
883
Buy Since 27-Mar-2023
$55
$23.98 (77.30%)
$55
22 days ago
(15-Sep-2026)
13/17 (76.47%)
$22.26 (67.99%)
437
Buy Since 23-Dec-2020
$55
$23.98 (77.30%)
$52
1 months 20 days ago
(17-Aug-2026)
8/10 (80%)
$17.13 (45.23%)
1254
Buy Since 08-Jul-2025
$52
$20.98 (67.63%)
$17
1 months 25 days ago
(12-Aug-2026)
1/2 (50%)
$13.02 (33.40%)
125
Buy Since 08-Dec-2023
$67
$28.9 (75.85%)
9 months 18 days ago
(19-Dec-2025)
8/9 (88.89%)
$27.45 (69.41%)
348
Which stock is Christopher Liu most bullish on?
What Year was the first public recommendation made by Christopher Liu?
